



GLAND PHARMA LIMITED

July 21, 2022

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra
(East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Newspaper advertisement pertaining to Unaudited Financial Results of Q1FY2023

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed copies of the newspaper advertisement pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2022. The advertisements were published in English and Telugu newspapers.

This is for your information and records.

Yours truly,

For Gland Pharma Limited



Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer

Encl: As mentioned above

Regd. Office:

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India
Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office:

Plot No. 11 & 84, TSIC Phase: IV
Pashamylaram (V), Patancheru (M), Sangareddy District
Hyderabad 502307, Telangana, India
Tel: +91-8455-699999



GLAND PHARMA LIMITED

Corporate Identification Number: L24239TG1978PLC002276

Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandhi Maisamma 'X' Roads, D.P. Pally,
Dundigal - Gandhi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India
Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.com

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in million)

| Particulars | Quarter ended | | | Year ended |
|---|---------------|-----------|-----------|------------|
| | 30-Jun-22 | 31-Mar-22 | 30-Jun-21 | 31-Mar-22 |
| | Unaudited | Audited | Unaudited | Audited |
| Revenue from operations | 8,568.98 | 11,030.14 | 11,539.00 | 44,007.08 |
| Profit before tax | 3,084.99 | 3,804.84 | 4,718.40 | 16,185.52 |
| Profit for the period/year | 2,291.69 | 2,859.02 | 3,506.52 | 12,116.64 |
| Total comprehensive income (after taxes) | 2,293.63 | 2,856.29 | 3,503.76 | 12,112.06 |
| Paid up equity share capital (Face value of ₹1/- each) | 164.65 | 164.30 | 163.90 | 164.30 |
| Other equity | | | | 71,411.91 |
| Earnings per equity share (Face value of ₹1/- each): (Not annualised for the quarter) | | | | |
| Basic (₹) | 13.93 | 17.40 | 21.41 | 73.81 |
| Diluted (₹) | 13.92 | 17.36 | 21.37 | 73.64 |

Additional information on Standalone Financial Results is as follows:

(₹ in million)

| Particulars | Quarter ended | | | Year ended |
|----------------------------|---------------|-----------|-----------|------------|
| | 30-Jun-22 | 31-Mar-22 | 30-Jun-21 | 31-Mar-22 |
| | Unaudited | Audited | Unaudited | Audited |
| Revenue from operations | 8,568.98 | 11,030.14 | 11,539.00 | 44,007.08 |
| Profit before tax | 3,087.84 | 3,805.58 | 4,718.63 | 16,190.43 |
| Profit for the period/year | 2,294.54 | 2,859.76 | 3,506.75 | 12,121.55 |

Notes:

- The Unaudited Consolidated Financial Results for the quarter ended June 30, 2022 ("Unaudited Consolidated Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 20, 2022.
- The above is an extract of the detailed format of quarter ended Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Company's website (www.glandpharma.com) and on the website of the National Stock Exchange of India Limited (www.nseindia.com) and BSE Limited (www.bseindia.com).

For and on behalf of the Board
Gland Pharma Limited
 Sd/-
Srinivas Sadu
 Managing Director and CEO
 DIN No. 06900659

Hyderabad
 July 20, 2022



GLAND PHARMA LIMITED

Corporate Identification Number: L24239TG1978PLC002276
 Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandhi Maisamma 'X' Roads, D.P. Pally, Dundigal - Gandhi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999;
 Website: www.glandpharma.com; E-mail: investors@glandpharma.com

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in million)

| Particulars | Quarter ended | | | Year ended |
|---|---------------|-----------|-----------|------------|
| | 30-Jun-22 | 31-Mar-22 | 30-Jun-21 | 31-Mar-22 |
| | Unaudited | Audited | Unaudited | Audited |
| Revenue from operations | 8,568.98 | 11,030.14 | 11,539.00 | 44,007.08 |
| Profit before tax | 3,084.99 | 3,804.84 | 4,718.40 | 16,185.52 |
| Profit for the period/year | 2,291.69 | 2,859.02 | 3,506.52 | 12,116.64 |
| Total comprehensive income (after taxes) | 2,293.63 | 2,856.29 | 3,503.76 | 12,112.06 |
| Paid up equity share capital (Face value of ₹1/- each) | 164.65 | 164.30 | 163.90 | 164.30 |
| Other equity | | | | 71,411.91 |
| Earnings per equity share (Face value of ₹1/- each): (Not annualised for the quarter) | | | | |
| Basic (₹) | 13.93 | 17.40 | 21.41 | 73.81 |
| Diluted (₹) | 13.92 | 17.36 | 21.37 | 73.64 |

Additional Information on Standalone Financial Results is as follows: (₹ in million)

| Particulars | Quarter ended | | | Year ended |
|----------------------------|---------------|-----------|-----------|------------|
| | 30-Jun-22 | 31-Mar-22 | 30-Jun-21 | 31-Mar-22 |
| | Unaudited | Audited | Unaudited | Audited |
| Revenue from operations | 8,568.98 | 11,030.14 | 11,539.00 | 44,007.08 |
| Profit before tax | 3,087.84 | 3,805.58 | 4,718.63 | 16,190.43 |
| Profit for the period/year | 2,294.54 | 2,859.76 | 3,506.75 | 12,121.55 |

Notes:

1. The Unaudited Consolidated Financial Results for the quarter ended June 30, 2022 ("Unaudited Consolidated Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 20, 2022.
2. The above is an extract of the detailed format of quarter ended Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Company's website (www.glandpharma.com) and on the website of the National Stock Exchange of India Limited (www.nseindia.com) and BSE Limited (www.bseindia.com).

For and on behalf of the Board

Gland Pharma Limited

Sd/-

Srinivas Sadu

Managing Director and CEO

DIN No. 06900659

Hyderabad
July 20, 2022



GLAND PHARMA LIMITED

Corporate Identification Number: L24239TG1978PLC002276
 Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandhi Maisamma 'X' Roads, D.P. Pally, Dundigal - Gandhi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999;
 Website: www.glandpharma.com; E-mail: investors@glandpharma.com

జూన్ 30, 2022లో ముగిసిన త్రైమాసికం కొరకు ఆడిట్ చేయని కన్సాలిడేటెడ్ ఆర్థిక ఫలితాల యొక్క సారాంశం

(₹ మిలియన్లలో)

| వివరములు | ముగిసిన త్రైమాసికం | | | ముగిసిన సంవత్సరం |
|---|--------------------|---------------|---------------|------------------|
| | 30-జూన్-22 | 31-మార్చి-22 | 30-జూన్-21 | 31-మార్చి-22 |
| | ఆడిట్ చేయనివి | ఆడిట్ చేసినవి | ఆడిట్ చేయనివి | ఆడిట్ చేసినవి |
| కార్యకలాపాల నుండి ఆదాయం | 8,568.98 | 11,030.14 | 11,539.00 | 44,007.08 |
| పన్నుకుముందు లాభం | 3,084.99 | 3,804.84 | 4,718.40 | 16,185.52 |
| కాలం / సంవత్సరం కొరకు లాభం | 2,291.69 | 2,859.02 | 3,506.52 | 12,116.64 |
| మొత్తం సమగ్ర ఆదాయం | 2,293.63 | 2,856.29 | 3,503.76 | 12,112.06 |
| (పన్నుల తరువాత) | | | | |
| చెల్లించిన ఈక్విటీ వాటా మూలధనం | 164.65 | 164.30 | 163.90 | 164.30 |
| (ముఖ విలువ ₹ 1/- చొప్పున) | | | | |
| ఇతర ఈక్విటీ | | | | 71,411.91 |
| ప్రతి వాటా ఆదానాలు | | | | |
| (ముఖ విలువ ₹ 1/- చొప్పున) (త్రైమాసిక కొరకు వార్షికరించబడినవి) | | | | |
| బేసిక్ (₹) | 13.93 | 17.40 | 21.41 | 73.81 |
| డైల్యూటెడ్ (₹) | 13.92 | 17.36 | 21.37 | 73.64 |

స్టాండ్ అలోన్ ఆర్థిక ఫలితాలపై అదనపు సమాచారం దిగువ ఇవ్వబడినది.

| వివరములు | ముగిసిన త్రైమాసికం | | | ముగిసిన సంవత్సరం |
|----------------------------|--------------------|---------------|---------------|------------------|
| | 30-జూన్-22 | 31-మార్చి-22 | 30-జూన్-21 | 31-మార్చి-22 |
| | ఆడిట్ చేయనివి | ఆడిట్ చేసినవి | ఆడిట్ చేయనివి | ఆడిట్ చేసినవి |
| కార్యకలాపాల నుండి ఆదాయం | 8,568.98 | 11,030.14 | 11,539.00 | 44,007.08 |
| పన్నుకుముందు లాభం | 3,087.84 | 3,805.58 | 4,718.63 | 16,190.43 |
| కాలం / సంవత్సరం కొరకు లాభం | 2,294.54 | 2,859.76 | 3,506.75 | 12,121.55 |

గమనిక:

- కంపెనీ యొక్క ("ఆడిట్ చేయని కన్సాలిడేటెడ్ ఆర్థిక ఫలితాలు") జూన్ 30, 2022లో ముగిసిన త్రైమాసికం కొరకు ఆడిట్ చేయని కన్సాలిడేటెడ్ ఆర్థిక ఫలితాలు ఆడిట్ కమిటీచే సమీక్షించబడినవి మరియు జులై 20, 2022న జరిగిన వారి సమావేశం వద్ద డైరెక్టర్ల బోర్డుచే ఆమోదించబడినవి.
- సిబి (రిస్పింగ్ ఆజ్ఞాగ్రాంట్) మరియు డిన్ క్లీజర్ ఆఫ్ కంప్లైన్స్, 2015 యొక్క రెగ్యులేషన్ 33 క్రింద స్టాక్ ఎక్స్ఛేంజీలతో దాఖలు చేయబడిన ఆడిట్ చేయని ఆర్థిక ఫలితాలు ముగిసిన త్రైమాసికం యొక్క వివరణాత్మక నమూనా యొక్క సారాంశం పైన ఇవ్వబడినది. ఆడిట్ చేయని ఆర్థిక ఫలితాల యొక్క పూర్తి నమూనా కంపెనీ యొక్క వెబ్సైట్ (www.glandpharma.com) మరియు నేషనల్ స్టాక్ ఎక్స్ఛేంజీ ఆఫ్ ఇండియా లిమిటెడ్ యొక్క వెబ్సైట్ (www.nseindia.com) మరియు బిఎస్ఇ లిమిటెడ్ (www.bseindia.com) పై కూడా పొందవచ్చును.

For and on behalf of the Board
Gland Pharma Limited
 Sd/-
Srinivas Sadu
Managing Director and CEO
 DIN No. 06900659

Hyderabad
 July 20, 2022